351 related articles for article (PubMed ID: 15556807)
1. The promise of minocycline in neurology.
Yong VW; Wells J; Giuliani F; Casha S; Power C; Metz LM
Lancet Neurol; 2004 Dec; 3(12):744-51. PubMed ID: 15556807
[TBL] [Abstract][Full Text] [Related]
2. Lack of neuroprotective effects of simvastatin and minocycline in a model of cervical spinal cord injury.
Lee JH; Tigchelaar S; Liu J; Stammers AM; Streijger F; Tetzlaff W; Kwon BK
Exp Neurol; 2010 Sep; 225(1):219-30. PubMed ID: 20599974
[TBL] [Abstract][Full Text] [Related]
3. Reconnoitering the transformative journey of minocycline from an antibiotic to an antiepileptic drug.
Singh T; Thapliyal S; Bhatia S; Singh V; Singh M; Singh H; Kumar A; Mishra A
Life Sci; 2022 Mar; 293():120346. PubMed ID: 35065989
[TBL] [Abstract][Full Text] [Related]
4. Clinical potential of minocycline for neurodegenerative disorders.
Blum D; Chtarto A; Tenenbaum L; Brotchi J; Levivier M
Neurobiol Dis; 2004 Dec; 17(3):359-66. PubMed ID: 15571972
[TBL] [Abstract][Full Text] [Related]
5. Results of a phase II placebo-controlled randomized trial of minocycline in acute spinal cord injury.
Casha S; Zygun D; McGowan MD; Bains I; Yong VW; Hurlbert RJ
Brain; 2012 Apr; 135(Pt 4):1224-36. PubMed ID: 22505632
[TBL] [Abstract][Full Text] [Related]
6. Antibiotics acting as neuroprotectants via mechanisms independent of their anti-infective activities.
Stock ML; Fiedler KJ; Acharya S; Lange JK; Mlynarczyk GS; Anderson SJ; McCormack GR; Kanuri SH; Kondru NC; Brewer MT; Carlson SA
Neuropharmacology; 2013 Oct; 73():174-82. PubMed ID: 23748053
[TBL] [Abstract][Full Text] [Related]
7. Stem cell-based cell therapy in neurological diseases: a review.
Kim SU; de Vellis J
J Neurosci Res; 2009 Aug; 87(10):2183-200. PubMed ID: 19301431
[TBL] [Abstract][Full Text] [Related]
8. NMDA receptors in clinical neurology: excitatory times ahead.
Kalia LV; Kalia SK; Salter MW
Lancet Neurol; 2008 Aug; 7(8):742-55. PubMed ID: 18635022
[TBL] [Abstract][Full Text] [Related]
9. Minocycline reduces lipopolysaccharide-induced neurological dysfunction and brain injury in the neonatal rat.
Fan LW; Pang Y; Lin S; Tien LT; Ma T; Rhodes PG; Cai Z
J Neurosci Res; 2005 Oct; 82(1):71-82. PubMed ID: 16118791
[TBL] [Abstract][Full Text] [Related]
10. Minocycline neuroprotects, reduces microgliosis, and inhibits caspase protease expression early after spinal cord injury.
Festoff BW; Ameenuddin S; Arnold PM; Wong A; Santacruz KS; Citron BA
J Neurochem; 2006 Jun; 97(5):1314-26. PubMed ID: 16638021
[TBL] [Abstract][Full Text] [Related]
11. Minocycline attenuates brain edema, brain atrophy and neurological deficits after intracerebral hemorrhage.
Wu J; Yang S; Hua Y; Liu W; Keep RF; Xi G
Acta Neurochir Suppl; 2010; 106():147-50. PubMed ID: 19812938
[TBL] [Abstract][Full Text] [Related]
12. Clinical Uses of Melatonin in Neurological Diseases and Mental and Behavioural Disorders.
Sanchez-Barcelo EJ; Rueda N; Mediavilla MD; Martinez-Cue C; Reiter RJ
Curr Med Chem; 2017 Nov; 24(35):3851-3878. PubMed ID: 28721826
[TBL] [Abstract][Full Text] [Related]
13. The prospects of minocycline in multiple sclerosis.
Chen X; Ma X; Jiang Y; Pi R; Liu Y; Ma L
J Neuroimmunol; 2011 Jun; 235(1-2):1-8. PubMed ID: 21565409
[TBL] [Abstract][Full Text] [Related]
14. Prospects for minocycline neuroprotection.
Plane JM; Shen Y; Pleasure DE; Deng W
Arch Neurol; 2010 Dec; 67(12):1442-8. PubMed ID: 20697034
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic effects of progesterone in animal models of neurological disorders.
De Nicola AF; Coronel F; Garay LI; Gargiulo-Monachelli G; Gonzalez Deniselle MC; Gonzalez SL; Labombarda F; Meyer M; Guennoun R; Schumacher M
CNS Neurol Disord Drug Targets; 2013 Dec; 12(8):1205-18. PubMed ID: 24040821
[TBL] [Abstract][Full Text] [Related]
16. [Minocycline for the treatment of amyotrophic lateral sclerosis: neuroprotector or neurotoxin? Reflections on another failure of translational medicine].
Gámez J
Neurologia; 2008 Oct; 23(8):484-93. PubMed ID: 18802797
[TBL] [Abstract][Full Text] [Related]
17. Mechanisms and therapeutic implications of the placebo effect in neurological and psychiatric conditions.
Murray D; Stoessl AJ
Pharmacol Ther; 2013 Dec; 140(3):306-18. PubMed ID: 23880289
[TBL] [Abstract][Full Text] [Related]
18. Rise and fall of minocycline in neuroprotection: need to promote publication of negative results.
Diguet E; Gross CE; Tison F; Bezard E
Exp Neurol; 2004 Sep; 189(1):1-4. PubMed ID: 15296829
[TBL] [Abstract][Full Text] [Related]
19. Hyperphosphorylated neurofilament NF-H as a biomarker of the efficacy of minocycline therapy for spinal cord injury.
Ueno T; Ohori Y; Ito J; Hoshikawa S; Yamamoto S; Nakamura K; Tanaka S; Akai M; Tobimatsu Y; Ogata T
Spinal Cord; 2011 Mar; 49(3):333-6. PubMed ID: 20805831
[TBL] [Abstract][Full Text] [Related]
20. Interactions with GluR1 AMPA receptors could influence the therapeutic usefulness of minocycline in ALS.
Manev H; Manev R
Amyotroph Lateral Scler; 2009; 10(5-6):416-7. PubMed ID: 19922133
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
